Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
Japan will put the highest priority on the review of AstraZeneca’s COVID-19 vaccine, Health Minister Norihisa Tamura told reporters on the heels of its submission on February 5, welcoming the company’s plan to produce many of its shots domestically. AstraZeneca…
To read the full story
Related Article
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- JCR to Build New Manufacturing Facility for COVID-19 Vaccine
March 5, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
BUSINESS
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…